Safety Information | LOKELMA® (sodium zirconium cyclosilicate) 5g | 10g for oral suspension | For HCPs
A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia | American Society of Nephrology
PulmCrit - Sodium Zirconium Cyclosilicate for urgent treatment of hyperkalemia?
Lokelma for treating hyperkalaemia in China – Future Medicine India
Table 4 from Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review | Semantic Scholar
Drug Trials Snapshots: LOKELMA | FDA
A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia | American Society of Nephrology
Drug Trials Snapshots: LOKELMA | FDA
BUY sodium zirconium cyclosilicate (LOKELMA) 5 g/5g AstraZeneca Pharmaceuticals LP
Lokelma sodium zirconium cyclosilicate treatment for hyperkalaemia
Lokelma (Sodium Zirconium Cyclosilicate): Uses, Dosage, Side Effects, Interactions, Warning
Dosing and Administration for Dialysis and Non-Dialysis Patients | LOKELMA® (sodium zirconium cyclosilicate) 5g | 10g for oral suspension | For HCPs
These highlights do not include all the information needed to use LOKELMA® safely and effectively. See full prescribing information for LOKELMA®. LOKELMA® (sodium zirconium cyclosilicate) for oral suspension Initial U.S. Approval: 2018
PDF) Sodium Zirconium Cyclosilicate
Lokelma Full Prescribing Information, Dosage & Side Effects | MIMS Singapore
Dosing and Administration for Dialysis and Non-Dialysis Patients | LOKELMA® (sodium zirconium cyclosilicate) 5g | 10g for oral suspension | For HCPs
These highlights do not include all the information needed to use LOKELMA® safely and effectively. See full prescribing information for LOKELMA®. LOKELMA® (sodium zirconium cyclosilicate) for oral suspension Initial U.S. Approval: 2018
FDA Approves a Label Update for Lokelma to Include Dosing Guidance for Treatment of Hyperkalemia in ESRD on Hemodialysis | Specialty Pharma Journal
Drug Trials Snapshots: LOKELMA | FDA
Drug Trials Snapshots: LOKELMA | FDA
The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K+-binder Lokelma for maximisation of RAAS inhibition in CKD patients with heart failure | BMC Nephrology | Full Text
Drug Trials Snapshots: LOKELMA | FDA
Lokelma Full Prescribing Information, Dosage & Side Effects | MIMS Hong Kong
Summary of ZS-9 clinical studies. | Download Table
AstraZeneca's Lokelma shows significant effect in ESRD trial
